DKK 261.20
+4.70
(+1.83%)
As of Oct 20, 2026, 12:57 PM EDT
Price history
Novo Nordisk (NOVO-B) is trading up at DKK 261.20 (+1.83%) on Europe, as of the latest quote. It is a Europe constituent in the Health Care sector.
About Novo Nordisk
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Recent News (20)
-
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 19 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of…
-
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
-
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 12 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of…
-
-
-
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? The Globe and Mail
-
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Yahoo Finance
-
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? The Globe and Mail
-
-
-
-
-
-
-
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
-
Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight The expected launch of potential therapies such as Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed…
-
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
-
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 14 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council …
-
Morgan Stanley downgrades Novo Nordisk stock rating on growth concerns
Morgan Stanley downgrades Novo Nordisk stock rating on growth concerns
-
More Health Care stocks
- BMY Bristol Myers Squibb
- JNJ Johnson & Johnson
- LLY Lilly (Eli)
- MRK Merck & Co.
- PFE Pfizer
- VTRS Viatris
- ZTS Zoetis
- A Agilent Technologies